IDG Capital Leads $67M Series C Round In Biotech Start-Up HiFiBiO Therapeutics

Login to View

HiFiBiO Therapeutics, a multinational biotherapeutics start-up that mobilizes the human immune system to combat disease, announced on Wednesday the completion of a US$67 million series C round of financing led by Boston-born investment company IDG Capital.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in